Procrit Shows Benefits Over Aranesp In Anemia Patient Study
Executive Summary
Cancer patients with chemotherapy-induced anemia who are treated with Procrit (epoetin alfa) experience a higher increase in hemoglobin levels than those treated with Aranesp (darbepoetin alfa), according to a study in the September issue of The Oncologist.
You may also be interested in...
Amgen To Study Aranesp Anemia Indication In Heart Failure Patients
Amgen is considering an appropriate design for a Phase III trial evaluating Aranesp (darbepoetin alfa) to treat anemia in patients with congestive heart failure
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials